Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. It is available in oral and intravenous formulations.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Erosive esophagitis
* Healing of duodenal ulcers
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Part of *Helicobacter pylori* eradication regimens
## Adult Dosing
* **GERD and Erosive Esophagitis:** 20 mg orally once daily. May increase to 40 mg orally once daily for severe erosive esophagitis.
* **Duodenal Ulcers:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose typically 40 mg orally or intravenously twice daily. Doses may be higher and adjusted based on acid output.
* **IV Administration:** 40 mg intravenously once daily. For pathological hypersecretory conditions, may require higher doses administered as continuous infusion or intermittent dosing.
* **H. pylori Eradication:** Typically 40 mg orally twice daily in combination with antibiotics and sometimes bismuth for 7-14 days.
## Pediatric Dosing
Dosing varies by age and indication. Consult specific pediatric guidelines. Examples include:
* **GERD (12 years and older):** 20 mg orally once daily. May increase to 40 mg orally once daily.
* **Erosive Esophagitis (5 years and older):** 20-40 mg orally once daily depending on severity.
## Dose Adjustments
No dose adjustment is typically required for hepatic or renal impairment, although caution may be advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Concomitant use with rilpivirine.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Serious: *Clostridium difficile*-associated diarrhea, bone fracture risk (long-term use), hypomagnesemia (long-term use), vitamin B12 deficiency (long-term use), fundic gland polyps.
## Key Drug Interactions
* **Rilpivirine:** Pantoprazole increases plasma concentrations of rilpivirine; contra-indicated.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **Clopidogrel:** Potential for reduced antiplatelet effect, though clinical significance is debated.
* **Drugs Dependent on Gastric pH:** Pantoprazole can alter gastric pH, affecting absorption of drugs like ketoconazole, itraconazole, iron salts, and mycophenolate mofetil.
* **CYP2C19 Substrates:** Pantoprazole can inhibit CYP2C19, potentially increasing levels of drugs metabolized by this enzyme (e.g., citalopram, clopidogrel).
## Monitoring
* Monitor for signs and symptoms of *C. difficile* infection.
* Consider monitoring serum magnesium levels with prolonged therapy (>3 months), especially with concomitant diuretic use.
* Monitor for signs of vitamin B12 deficiency with prolonged therapy.
* Monitor for bone pain or fracture risk.
## Clinical Pearls
* Administer oral pantoprazole 30-60 minutes before a meal for optimal efficacy.
* Pantoprazole delayed-release tablets and capsules should not be crushed or chewed.
* Pantoprazole for injection requires reconstitution and is typically administered as an infusion.
* Consider the risk of bone fractures, *C. difficile* infection, and hypomagnesemia with long-term PPI use.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for comprehensive prescribing information. Always consult the current official prescribing information and local institutional protocols for complete and up-to-date guidance.
